Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SARAFEM vs CELEXA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SARAFEM (fluoxetine) is a selective serotonin reuptake inhibitor (SSRI). It potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, enhancing serotonin effects in the synaptic cleft.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.
Major depressive disorder,Obsessive-compulsive disorder,Bulimia nervosa,Panic disorder,Premenstrual dysphoric disorder (PMDD)
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
10-20 mg orally once daily initially, may increase to 40 mg/day after 3 weeks if needed; maximum 80 mg/day
20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.
Fluoxetine: 4-6 days after single dose, 4-16 days after chronic dosing; norfluoxetine: 4-16 days after single dose, up to 16-20 days after chronic dosing. The long half-life minimizes withdrawal symptoms and allows for once-weekly dosing.
Terminal elimination half-life is approximately 35 hours (range 23–45 h) in healthy adults. This long half-life allows once-daily dosing; steady state is reached in about 1 week. In elderly patients, half-life may extend to 45–90 hours.
Fluoxetine is extensively metabolized in the liver via the cytochrome P450 enzyme system, primarily CYP2D6, to its active metabolite norfluoxetine.
Hepatic via CYP2C19 (major), CYP3A4, and CYP2D6; active metabolites: S-demethylcitalopram and didemethylcitalopram.
Primarily renal excretion of fluoxetine (10%) and its active metabolite norfluoxetine (7.5%) as unchanged drug; the remainder is excreted as conjugates and other metabolites. Approximately 2.5% is excreted in feces.
Primarily renal: 75% as metabolites (10% as parent citalopram, 65% as desmethylcitalopram, didesmethylcitalopram, and citalopram-N-oxide). Fecal excretion accounts for approximately 20% of the dose. Biliary excretion minimal.
Approximately 94.5% bound to plasma proteins, including albumin and alpha-1-acid glycoprotein.
Approximately 80% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). Binding is independent of drug concentration.
Fluoxetine: 12-43 L/kg; norfluoxetine: 8-43 L/kg. Large Vd indicates extensive tissue distribution, with brain concentrations higher than plasma.
Mean Vd is 12 L/kg (range 8–16 L/kg). This large Vd indicates extensive extravascular distribution, including CNS penetration. High Vd contributes to the long half-life.
Oral: 72% (range 50-100%), with food not significantly affecting absorption.
Oral bioavailability is approximately 80% (range 60–90%). No significant first-pass metabolism. Food does not affect bioavailability.
No adjustment for GFR 20-50 m L/min; avoid use if GFR <20 m L/min
GFR >20 m L/min: no adjustment; GFR ≤20 m L/min: maximum 20 mg/day; not recommended for GFR <10 m L/min.
Child-Pugh A: 10 mg/day; Child-Pugh B: 10 mg/day with caution; Child-Pugh C: not recommended
Child-Pugh Class A: 10 mg once daily; Child-Pugh Class B or C: maximum 20 mg/day with careful titration.
8-18 years: 10 mg orally once daily initially, may increase to 20 mg/day after 2 weeks
Adolescents 12-17 years: 10 mg orally once daily initially, may increase to 20 mg once daily after 3 weeks; maximum 20 mg/day. Children <12 years: not approved.
Initial 10 mg orally once daily; increase slowly with minimum effective dose; CYP2D6 interaction concerns
Patients >60 years: 10 mg orally once daily initially, maximum 20 mg once daily.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Clinical worsening and suicide risk,Serotonin syndrome,Allergic reactions and rash,Abnormal bleeding,Activation of mania/hypomania,Seizures,Angle-closure glaucoma,Hyponatremia,QT prolongation
QT prolongation, serotonin syndrome, hyponatremia, increased risk of bleeding, activation of mania/hypomania, seizures, angle-closure glaucoma, sexual dysfunction, and discontinuation syndrome.
Concomitant use with MAOIs or within 14 days of discontinuing an MAOI,Concomitant use with pimozide or thioridazine,Known hypersensitivity to fluoxetine or any component of the formulation
Concomitant use with MAOIs or within 14 days of MAOI use, concomitant use with pimozide, hypersensitivity to citalopram or any excipients.
No specific food restrictions. Avoid concurrent use of St. John's wort, tryptophan, or 5-HTP due to risk of serotonin syndrome. Grapefruit may increase fluoxetine levels; limit intake.
No specific food interactions. Avoid grapefruit and grapefruit juice as they may increase citalopram levels via CYP3A4 inhibition. Alcohol may exacerbate CNS depression and should be avoided.
First trimester: Associated with increased risk of cardiac malformations (e.g., ventricular septal defects) and persistent pulmonary hypertension of the newborn. Second/third trimester: Risk of preterm birth, low birth weight, and neonatal adaptation syndrome (jitteriness, hypertonia, poor feeding).
First trimester: Data insufficient to definitively assess major malformation risk; some studies suggest small increased risk of cardiac defects (e.g., septal defects). Second/Third trimester: Risk of persistent pulmonary hypertension of the newborn (PPHN), preterm birth, low birth weight; late third trimester exposure may cause neonatal adaptation syndrome (irritability, respiratory distress, feeding difficulties).
Fluoxetine is excreted into breast milk; M/P ratio ~0.3-0.6. Relative infant dose estimated at 2-4% of maternal dose. Monitor infant for drowsiness, poor feeding, and irritability.
Citalopram is excreted into breast milk; average infant dose relative to maternal weight-adjusted dose is 3.9% (range 1.7-8.5%). Milk-to-plasma ratio (M/P) approximately 1.5. Cases of adverse effects in breastfed infants (excessive somnolence, poor feeding) reported; caution with higher maternal doses. Benefits of breastfeeding generally outweigh risks for mild cases, but alternative agents with lower M/P (e.g., sertraline, paroxetine) may be preferred for moderate-severe depression.
Increased clearance and volume of distribution during pregnancy may require dose adjustment. Consider dose increase by 50-100% in third trimester, with postpartum taper to pre-pregnancy dose. Monitor trough levels if available.
Pregnancy may reduce citalopram plasma concentrations by 30-50% due to increased volume of distribution and enhanced hepatic clearance (CYP2C19 induction). Dose adjustment should be guided by clinical response (depressive symptom monitoring) and trough serum concentrations if available. A 30-50% dose increase (e.g., from 20 mg to 30-40 mg) may be needed, especially in third trimester. Postpartum: Dose should be tapered back to pre-pregnancy levels within 1–2 weeks to avoid toxicity.
SARAFEM (fluoxetine 10 mg) is indicated for premenstrual dysphoric disorder (PMDD). Dosing is typically 20 mg/day continuous or 20 mg/day intermittent (starting 14 days before menses). Onset of benefit may take 1-2 cycles. Monitor for serotonin syndrome, especially if combined with other serotonergic drugs. Discontinue gradually to avoid withdrawal symptoms. Suicidal thinking risk warning applies, particularly in young adults.
Celexa (citalopram) is an SSRI antidepressant. Key pearls: (1) Max dose 40 mg/day due to QT prolongation risk at higher doses; (2) CYP2C19 and CYP3A4 metabolism; avoid with MAOIs and linezolid; (3) Onset of therapeutic effect takes 2-4 weeks; (4) More selective for serotonin reuptake than fluoxetine or paroxetine, with fewer drug interactions; (5) May cause mild SIADH in elderly; (6) Abrupt discontinuation can cause withdrawal syndrome; (7) Electrolyte monitoring recommended in patients at risk for QT prolongation.
Take SARAFEM exactly as prescribed, with or without food.,It may take several weeks to feel the full benefit; do not stop suddenly.,Report any worsening depression, suicidal thoughts, or unusual behavior changes immediately.,Avoid alcohol while taking this medication.,Inform your doctor of all other medications, especially MAOIs, triptans, or other antidepressants.,May cause drowsiness or dizziness; use caution when driving or operating machinery.
Take exactly as prescribed; do not increase dose without consulting your doctor.,It may take 2-4 weeks to feel the full benefit; do not stop abruptly.,Avoid alcohol while taking this medication.,Report any symptoms of serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, muscle stiffness) immediately.,Notify your doctor if you experience unusual bleeding or bruising, or if you have a history of QT prolongation or electrolyte disturbances.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SARAFEM vs CELEXA, answered by our medical review team.
SARAFEM is a SSRI Antidepressant that works by SARAFEM (fluoxetine) is a selective serotonin reuptake inhibitor (SSRI). It potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, enhancing serotonin effects in the synaptic cleft.. CELEXA is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SARAFEM and CELEXA depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SARAFEM is: 10-20 mg orally once daily initially, may increase to 40 mg/day after 3 weeks if needed; maximum 80 mg/day. The standard adult dose of CELEXA is: 20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SARAFEM and CELEXA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SARAFEM is classified as Category C. First trimester: Associated with increased risk of cardiac malformations (e.g., ventricular septal defects) and persistent pulmonary hypertension of the newborn. Second/third trime. CELEXA is classified as Category C. First trimester: Data insufficient to definitively assess major malformation risk; some studies suggest small increased risk of cardiac defects (e.g., septal defects). Second/Third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.